Major increase in endopeptidase activity of human cathepsin B upon removal of occluding loop contacts. 1997

D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
Biotechnology Research Institute, National Research Council of Canada, Montreal, Quebec, H4P2R2 Canada.

The main feature distinguishing cathepsin B from other cysteine proteases of the papain family is the presence of a large insertion loop, termed the occluding loop, which occupies the S' subsites of the enzyme. The loop is held in place mainly by two contacts with the rest of the enzyme, involving residues His110 and Arg116 on the loop that form salt bridges with Asp22 and Asp224, respectively. The influence of this loop on the endopeptidase activity of cathepsin B has been investigated using site-directed mutagenesis and internally quenched fluorogenic (IQF) substrates. Wild-type cathepsin B displays poor activity against the substrates Abz-AFRSAAQ-EDDnp and Abz-QVVAGA-EDDnp as compared to cathepsin L and papain. Appreciable increases in kcat/KM were observed for cathepsin B containing the single mutations D22A, H110A, R116A, and D224A. The highest activity however is observed for mutants where both loop to enzyme contacts are disrupted. For the triple-mutant D22A/H110A/R116A, an optimum kcat/KM value of 12 x 10(5) M-1 s-1 was obtained for hydrolysis of Abz-AFRSAAQ-EDDnp, which corresponds to a 600-fold increase relative to wild-type cathepsin B and approaches the level of activity observed with cathepsin L or papain. By comparison, the mutations have little effect on the hydrolysis of Cbz-FR-MCA. The influence of the mutations on the pH dependency of activity also indicates that the complexity of pH activity profiles normally observed for cathepsin B is related to the presence of the occluding loop. The major increase in endopeptidase activity is attributed to an increase in loop "flexibility" and suggests that the occluding loop might move when an endopeptidase substrate binds to the enzyme. The possible contribution of these interactions in regulating endopeptidase activity and the implications for cathepsin B activity in physiological or pathological conditions are discussed.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010450 Endopeptidases A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS. Endopeptidase,Peptide Peptidohydrolases
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D002401 Cathepsin B A lysosomal cysteine proteinase with a specificity similar to that of PAPAIN. The enzyme is present in a variety of tissues and is important in many physiological and pathological processes. In pathology, cathepsin B has been found to be involved in DEMYELINATION; EMPHYSEMA; RHEUMATOID ARTHRITIS, and NEOPLASM INVASIVENESS. Cathepsin B-Like Proteinase,Cathepsin B1,Cathepsin B Like Proteinase,Proteinase, Cathepsin B-Like
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.

Related Publications

D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
January 1997, The Journal of biological chemistry,
D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
July 2010, Journal of molecular biology,
D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
August 2002, Bioorganic chemistry,
D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
August 2008, The Journal of biological chemistry,
D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
March 2016, ACS medicinal chemistry letters,
D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
December 2000, FEBS letters,
D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
April 1981, The Journal of laboratory and clinical medicine,
D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
January 1998, FEBS letters,
D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
January 1990, Neoplasma,
D K Nägler, and A C Storer, and F C Portaro, and E Carmona, and L Juliano, and R Ménard
January 1968, Acta dermato-venereologica,
Copied contents to your clipboard!